BR100 Decreased By (-0.03%)
BR30 Decreased By (-0.19%)
KSE100 Decreased By (-0.24%)
KSE30 Decreased By (-0.44%)
BECO 5.88 Decreased By ▼ -0.15 (-2.49%)
BML 57.79 Increased By ▲ 5.04 (9.55%)
BOP 33.80 Decreased By ▼ -0.45 (-1.31%)
CNERGY 8.16 No Change ▼ 0.00 (0%)
DCL 11.79 Decreased By ▼ -0.55 (-4.46%)
FCCL 53.75 Decreased By ▼ -0.14 (-0.26%)
FCSC 5.53 Increased By ▲ 0.31 (5.94%)
FFL 17.83 Decreased By ▼ -0.20 (-1.11%)
FNEL 1.30 No Change ▼ 0.00 (0%)
HUMNL 11.15 Increased By ▲ 0.15 (1.36%)
KEL 8.09 Decreased By ▼ -0.02 (-0.25%)
KOSM 5.45 Increased By ▲ 0.07 (1.3%)
MLCF 88.13 Increased By ▲ 0.08 (0.09%)
NBP 183.50 Decreased By ▼ -2.98 (-1.6%)
PACE 11.66 Increased By ▲ 0.94 (8.77%)
PAEL 40.25 Increased By ▲ 0.31 (0.78%)
PIAHCLA 26.11 Decreased By ▼ -0.06 (-0.23%)
PIBTL 17.24 Decreased By ▼ -0.08 (-0.46%)
PPL 231.00 Decreased By ▼ -1.78 (-0.76%)
PRL 34.38 Decreased By ▼ -0.57 (-1.63%)
PTC 67.80 Increased By ▲ 0.24 (0.36%)
SEARL 91.00 Increased By ▲ 0.07 (0.08%)
SSGC 26.88 Decreased By ▼ -0.29 (-1.07%)
TELE 8.57 No Change ▼ 0.00 (0%)
THCCL 66.14 Increased By ▲ 6.01 (10%)
TPLP 9.43 Increased By ▲ 0.67 (7.65%)
TREET 24.57 Increased By ▲ 0.03 (0.12%)
TRG 71.82 Increased By ▲ 0.07 (0.1%)
WAVES 10.98 Increased By ▲ 1.00 (10.02%)
WTL 1.26 No Change ▼ 0.00 (0%)
Business & Finance

Pfizer to pursue bringing COVID-19 vaccine to India after import relaxation

  • "We have noted the recent announcement with regard to the regulatory pathway for global vaccines," a Pfizer spokesperson told Reuters in an email.
  • "We remain committed to continuing our engagement with the government towards making the Pfizer and BioNTech vaccine available for use in the government's immunisation program."
Published April 13, 2021 Updated April 13, 2021 08:29pm
By

NEW DELHI: Pfizer Inc said on Tuesday it would work towards bringing the COVID-19 vaccine it developed with Germany's BioNTech to India after the government eased import rules, after withdrawing its application in February.

"We have noted the recent announcement with regard to the regulatory pathway for global vaccines," a Pfizer spokesperson told Reuters in an email.

"We remain committed to continuing our engagement with the government towards making the Pfizer and BioNTech vaccine available for use in the government's immunisation program."

Comments

Comments are closed for this article.